Episode 49
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:
- Introduction (0:00)
- Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)
- Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)
- Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01)
- Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22)
- Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37)
